- Home
- IMRN
IMRN
Immuron Limited
as 04-23-2025 4:00pm EST
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 10.1M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 22.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $2.87 | Next Earning Date: | 05-06-2025 |
| Revenue: | $4,048,286 | Revenue Growth: | 82.90% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immuron Limited News
IMRN Breaking Stock News: Dive into IMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Immuron Travelan® highest sales in history
GlobeNewswire
2 months ago
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
GlobeNewswire
2 months ago
Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
GlobeNewswire
3 months ago
Immuron Travelan® continued strong sales growth
GlobeNewswire
3 months ago
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
GlobeNewswire
3 months ago
Immuron Announces Travelan® Clinical Trial Update
Simply Wall St.
3 months ago
Hartshead Resources And 2 Other Promising Penny Stocks On The ASX
GlobeNewswire
5 months ago
UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Compare IMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRN Immuron Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.